Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells

Oncogene

Volumn 31, Issue 14, 2012, Pages 1794-1803

  Wang, J ^a   Anderson, P D ^b   Luo, W ^a   Gius, D ^a,b   Roh, M ^b   Abdulkadir, S A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erk; gene expression; MYC; Pim1 kinase; tumorigenicity

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN KINASE PIM 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL SURVIVAL; CONTROLLED STUDY; GENE LOSS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-PIM-1; UP-REGULATION;

EID: 84860423643     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.371     Document Type: Article

References (31)

1. Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalona WJ, Milbrandt J. (2001). Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol 32: 935-939. (Pubitemid 32911315)
2. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ et al. (2000). Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31: 443-447. (Pubitemid 30262866)
3. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. (2004). Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43-49. (Pubitemid 38992921)
4. Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B, Jonkers J. (1999). Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res 59: 1773s-1777s. (Pubitemid 29165253)
5. Burton GR, Nagarajan R, Peterson CA, McGehee Jr RE. (2004). Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. Gene 329: 167-185. (Pubitemid 38366505)
6. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R et al. (2009a). Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am J Pathol 175: 400-411.
7. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. (2009b). Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114: 4150-4157.
8. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. (2005). Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 3: 443-451. (Pubitemid 41232606)
9. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. (1993). A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7: 671-682. (Pubitemid 23125266)
10. Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S et al. (2009). Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 206: 1957-1970.
11. Gu JJ, Wang Z, Reeves R, Magnuson NS. (2009). PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28: 4261-4271.
12. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. (2009). PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362-375.
13. Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, Laville M et al. (2010). Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 59: 61-70.
14. Kim J, Roh M, Abdulkadir SA. (2010). Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 10: 248.
15. Kolch W. (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351(Part 2): 289-305.
16. Laird PW, van der Lugt NM, Clarke A, Domen J, Linders K, McWhir J et al. (1993). In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 21: 4750-4755. (Pubitemid 23312750)
17. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I. (2007). Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67: 1761-1769. (Pubitemid 350228728)
18. Magnuson NS, Wang Z, Ding G, Reeves R. (2010). Why target PIM1 for cancer diagnosis and treatment? Future Oncol 6: 1461-1478.
19. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J et al. (2004). Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 24: 6104-6115. (Pubitemid 38787993)
20. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. (Pubitemid 36792858)
21. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. (2008). Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 68: 5076-5085.
22. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S et al. (2009). Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8: 2882-2893.
23. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C et al. (2005). Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130-6137. (Pubitemid 40280098)
24. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A et al. (2003). Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 63: 8079-8084. (Pubitemid 37549449)
25. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB et al. (2008). Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 44: 2144-2151.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
27. Tusher VG, Tibshirani R, Chu G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121. (Pubitemid 32397092)
28. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. (1991). Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 11: 1176-1179. (Pubitemid 21895472)
29. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML et al. (2010). Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29: 2477-2487.
30. Zhang Y, Wang Z, Li X, Magnuson NS. (2008). Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27: 4809-4819.
31. Zippo A, De Robertis A, Serafini R, Oliviero S. (2007). PIM1- dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 9: 932-944. (Pubitemid 47190448)